






# IGN 116 Targets And Eliminates Cancer Stem Cells (CSC)



# While the cancer market is growing, survival rates are still low. Why?

#### **Conventional chemotherapy does not cure all cancers**








excelen

Problem

#### This is because <u>not all cancer cells</u> are the same



Cancer Stem Cells (CSCs) give rise to all of the other tumor cells, establishing the hierarchy and heterogeneity of the tumor. CSC possess exclusive tumorigenic and metastatic potential, and are the drivers of tumorigenesis, chemoresistance and relapse.







excele

### **OUR Therapeutic Solution**

#### Therefore, we need to target the CSCs within the tumor










### **OUR Therapeutic Solution**

#### Therefore, we need to target the CSCs within the tumor



IGN116 exhibits a different

mode of action compared to

conventional anti-cancer drugs,

by targeting CSCs





## **Target population**

Our **target population** are patients with **CSC-driven** tumors, as the maintenance of these cancers **depend on CSCs**. We has focused on Pancreatic cancer as a model tumor, but this technology could be extended to many other cancers. For example (but not limited to):







## Current state of IGN116


	2018 - 2022	2022-2024 CaixaResearch
Discovery	Preclinical testing (in vitro & in vivo)	
Drug discovery phase:	Preclinical phase:	CRO led, non-regulatory in vivo studies (SAI & AMSlab)
Target discovery √ Identification of tumors	Mechanism of action √ Identification of MOA (inhibition of mtDNA transcription)	<ul> <li>✓ Analytical protocol for Ru detection (ICP-MS)</li> <li>✓ Initial PK study</li> </ul>
amenable to therapy	In vitro toxicity √ CRO led: Toxicity, Cardiotoxicity, Cytochrome interactions, Permeability, Plasma protein binding, metabolic stability	√ MTD study (i.v. bolus)
✓ Identification of cell type to be targeted (i.e., CSC)		$\checkmark$ PK & PD studies, Therapeutic index determination
✓ Identification of targets that can be targeted	In vivo efficacy and safety √ Efficacy in 6 PDAC PDX models (subcutaneous & orthotopic)	<ul> <li>✓ Single and repeat dose &amp; safety studies in 2 species</li> <li>CDMO led, Manufacturing (Galquimia)</li> <li>✓ Protocol for GMP-amenable scale-up and production</li> </ul>
Drug Discovery √ Hit discovery	✓ Efficacy in 2 CRC and 1 Osteosarcoma PDX models	Other ✓ Lower doses and alternative admin route studies
✓ Lead compound (IGN111/116)	$\checkmark$ CRO led in vitro toxicity studies and preliminary PK studies	$\checkmark$ Test in other tumors (NSCLC, NECs, Breast, CRC)
✓ Pre-formulation	✓ Maximum tolerated dose (MTD) determined	√ Test <b>analogues</b> in vitro & <b>in vivo</b>
✓ Synthesis (IGN111 & IGN116)	✓ <b>Dosing interval</b> and <b>admin route</b> studies	$\checkmark$ PK efficacy study with PDAC PDX
✓ Stability and degradation studies	Chemistry √ Scale up, protocols for detection by MS, and synthesis	✓ Regulatory & Pre-clinical roadmap  √ Business plan
<b>gain</b> CaixaResearch		USC excelenciauant

DE SANTIAGO DE COMPOSTELA



### Patent Family – IGN116

Cancer Therapy Market - Growth Rate by Region (2018)







### Multidisciplinary team

**IGN116** has developed from a multidisciplinary collaboration:





